CBD-Based Drug Reduces Pericarditis Pain And Inflammation, Shows New Clinical Study
Cardiol Therapeutics Inc. (NASDAQ:CRDL), a clinical-stage life sciences company, reported results from its Phase II open-label MAvERIC-Pilot study of CardiolRx, a cannabidiol-based therapy for treating symptomatic recurrent pericarditis. Cannabidiol (CBD) is a non-psychoactive compound found in the cannabis plant.
The study, presented at the American Heart Association Scientific Sessions 2024, showed sustained reductions in pericarditis pain and inflammation over 26 weeks.
“The data reported today show that patients enrolled in MAvERIC-Pilot, despite the severity of their disease, experienced clinically relevant and rapid reductions in both their pericarditis pain and C-reactive protein levels that were maintained throughout the study,” stated Dr. S. Allen Luis, co-director of the Pericardial Diseases Clinic and associate professor of Medicine in the Department of Cardiovascular Medicine at the Mayo Clinic. “In addition, results demonstrated a substantial reduction in pericarditis episodes per year as compared to the patients’ historical event rate prior to the study. Importantly, treatment was shown to be safe and well tolerated in a population who presented with significant disease burden. I look forward to …